-
Effectiveness of ChatGPT in explaining complex medical reports to patients
Authors:
Mengxuan Sun,
Ehud Reiter,
Anne E Kiltie,
George Ramsay,
Lisa Duncan,
Peter Murchie,
Rosalind Adam
Abstract:
Electronic health records contain detailed information about the medical condition of patients, but they are difficult for patients to understand even if they have access to them. We explore whether ChatGPT (GPT 4) can help explain multidisciplinary team (MDT) reports to colorectal and prostate cancer patients. These reports are written in dense medical language and assume clinical knowledge, so t…
▽ More
Electronic health records contain detailed information about the medical condition of patients, but they are difficult for patients to understand even if they have access to them. We explore whether ChatGPT (GPT 4) can help explain multidisciplinary team (MDT) reports to colorectal and prostate cancer patients. These reports are written in dense medical language and assume clinical knowledge, so they are a good test of the ability of ChatGPT to explain complex medical reports to patients. We asked clinicians and lay people (not patients) to review explanations and responses of ChatGPT. We also ran three focus groups (including cancer patients, caregivers, computer scientists, and clinicians) to discuss output of ChatGPT. Our studies highlighted issues with inaccurate information, inappropriate language, limited personalization, AI distrust, and challenges integrating large language models (LLMs) into clinical workflow. These issues will need to be resolved before LLMs can be used to explain complex personal medical information to patients.
△ Less
Submitted 22 June, 2024;
originally announced June 2024.
-
Follicle-stimulating hormone receptor: Advances and remaining challenges
Authors:
Francesco De Pascali,
Aurélie Tréfier,
Flavie Landomiel,
Véronique Bozon,
Gilles Bruneau,
Romain Yvinec,
Anne Poupon,
Pascale Crépieux,
Eric Reiter
Abstract:
Follicle-stimulating hormone (FSH) is produced in the pituitary and is essential for reproduction. It specifically binds to a membrane receptor (FSHR) expressed in somatic cells of the gonads. The FSH/FSHR system presents many peculiarities compared to classical G protein-coupled receptors (GPCRs). FSH is a large naturally heterogeneous heterodimeric glycoprotein. The FSHR is characterized by a ve…
▽ More
Follicle-stimulating hormone (FSH) is produced in the pituitary and is essential for reproduction. It specifically binds to a membrane receptor (FSHR) expressed in somatic cells of the gonads. The FSH/FSHR system presents many peculiarities compared to classical G protein-coupled receptors (GPCRs). FSH is a large naturally heterogeneous heterodimeric glycoprotein. The FSHR is characterized by a very large NH2-terminal extracellular domain, which binds the FSH and participates to the activation/inactivation switch of the receptor. Once activated, the FSHR couples to Gαs and, in some instances, to other Gα subunits. G protein-coupled receptor kinases and β-arrestins are also recruited to the FSHR and account for its desensitization, the control of its trafficking and its intracellular signalling. Of note, the FSHR internalization and recycling are very fast and involve very early endosomes instead of early endosomes. All the transduction mechanisms triggered upon FSH stimulation lead to the activation of a complex signalling network that controls gene expression by acting at multiple levels. The integration of these mechanisms leads to context-adapted responses from the target gonadal cells, but also indirectly affects the fate of germ cells. Depending of the physiological/developmental stage, FSH elicits proliferation, differentiation or apoptosis in order to maintain the homeostasis of the reproductive system. Pharmacological tools targeting FSHR recently came to the fore and open promising prospects both for basic research and therapeutic applications. This paper provides an updated review of the most salient aspects and peculiarities of FSHR biology and pharmacology.
△ Less
Submitted 31 July, 2018;
originally announced August 2018.
-
Human Luteinizing Hormone and Chorionic Gonadotropin Display Biased Agonism at the LH and LH/CG Receptors
Authors:
Laura Riccetti,
Romain Yvinec,
Danièle Klett,
Nathalie Gallay,
Yves Combarnous,
Eric Reiter,
Manuela Simoni,
Livio Casarini,
Mohammed Akli Ayoub
Abstract:
Human luteinizing hormone (LH) and chorionic gonadotropin (hCG) have been considered biologically equivalent because of their structural similarities and their binding to the same receptor; the LH/CGR. However, accumulating evidence suggest that LH/CGR differentially responds to the two hormones triggering differential intracellular signaling and steroidogenesis. The mechanistic basis of such diff…
▽ More
Human luteinizing hormone (LH) and chorionic gonadotropin (hCG) have been considered biologically equivalent because of their structural similarities and their binding to the same receptor; the LH/CGR. However, accumulating evidence suggest that LH/CGR differentially responds to the two hormones triggering differential intracellular signaling and steroidogenesis. The mechanistic basis of such differential responses remains mostly unknown. Here, we compared the abilities of recombinant rhLH and rhCG to elicit cAMP, β-arrestin 2 activation, and steroidogenesis in HEK293 cells and mouse Leydig tumor cells (mLTC-1). For this, BRET and FRET technologies were used allowing quantitative analyses of hormone activities in real-time and in living cells. Our data indicate that rhLH and rhCG differentially promote cell responses mediated by LH/CGR revealing interesting divergences in their potencies, efficacies and kinetics: rhCG was more potent than rhLH in both HEK293 and mLTC-1 cells. Interestingly, partial effects of rhLH were found on β-arrestin recruitment and on progesterone production compared to rhCG. Such a link was further supported by knockdown experiments. These pharmacological differences demonstrate that rhLH and rhCG act as natural biased agonists. The discovery of novel mechanisms associated with gonadotropin-specific action may ultimately help improve and personalize assisted reproduction technologies
△ Less
Submitted 31 July, 2018;
originally announced August 2018.
-
Profiling of FSHR Negative Allosteric Modulators on LH/CGR Reveals Biased Antagonism with Implications in Steroidogenesis
Authors:
Mohammed Akli Ayoub,
Romain Yvinec,
Gwenhaël Jégot,
James A. Dias,
Sonia-Maria Poli,
Anne Poupon,
Pascale Crépieux,
Eric Reiter
Abstract:
Biased signaling has recently emerged as an interesting mean to modulate the function of many G protein-coupled receptors (GPCRs). Previous studies reported two negative allosteric modulators (NAMs) of follicle-stimulating hormone receptor (FSHR), ADX68692 and ADX68693, with differential effects on FSHR-mediated steroidogenesis and ovulation. In this study, we attempted to pharmacologically profil…
▽ More
Biased signaling has recently emerged as an interesting mean to modulate the function of many G protein-coupled receptors (GPCRs). Previous studies reported two negative allosteric modulators (NAMs) of follicle-stimulating hormone receptor (FSHR), ADX68692 and ADX68693, with differential effects on FSHR-mediated steroidogenesis and ovulation. In this study, we attempted to pharmacologically profile these NAMs on the closely related luteinizing/chorionic gonadotropin hormone receptor (LH/CGR) with regards to its canonical Gs/cAMP pathway as well as β-arrestin recruitment in HEK293 cells. The NAMs effects on progesterone and testosterone production were also assessed in murine Leydig tumor cell line (mLTC-1). We found that both NAMs strongly antagonized LH/CGR signaling in both HEK293 and mLTC-1 cells. ADX68693 appeared more potent than ADX68692 to inhibit hCG-induced cAMP and β-arrestin 2 in HEK293 and mLTC-1 cells whereas no significant difference in their efficacy on hCG-promoted β-arrestin 2 recruitment. Interestingly, differential antagonism of the two NAMs on hCG-promoted steroidogenesis in mLTC-1 cells was observed with significant inhibition of testosterone but not progesterone production. These observations suggest biased effects of the two NAMs on LH/CGR-dependent pathways controlling steroidogenesis, which appeared to be different to that previously shown on FSHR. This also illustrates the complexity of signaling pathways controlling FSHR- and LH/CGR-mediated steroidogenesis, suggesting differential implication of cAMP and β-arrestins. Together, our data demonstrate that ADX68692 and ADX68693 are NAMs at the LH/CGR in addition to FSHR. These pharmacological characteristics are important to consider for potential contraceptive and therapeutic applications based on such compounds.
△ Less
Submitted 1 August, 2018;
originally announced August 2018.
-
Advances in computational modeling approaches in pituitary gonadotropin signaling
Authors:
Romain Yvinec,
Pascale Crépieux,
Eric Reiter,
Anne Poupon,
Frédérique Clément
Abstract:
Pituitary gonadotropins play an essential and pivotal role in the control of human and animal reproduction within the hypothalamic-pituitary-gonadal (HPG) axis. The computational modeling of pituitary gonadotropin signaling encompasses phenomena of different natures such as the dynamic encoding of gonadotropin secretion, and the intracellular cascades triggered by gonadotropin binding to their cog…
▽ More
Pituitary gonadotropins play an essential and pivotal role in the control of human and animal reproduction within the hypothalamic-pituitary-gonadal (HPG) axis. The computational modeling of pituitary gonadotropin signaling encompasses phenomena of different natures such as the dynamic encoding of gonadotropin secretion, and the intracellular cascades triggered by gonadotropin binding to their cognate receptors, resulting in a variety of biological outcomes. We overview historical and ongoing issues in modeling and data analysis related to gonadotropin secretion in the field of both physiology and neuro-endocrinology. We mention the different mathematical formalisms involved, their interest and limits. We discuss open statistical questions in signal analysis associated with key endocrine issues. We also review recent advances in the modeling of the intracellular pathways activated by gonadotropins, which yields promising development for innovative approaches in drug discovery. The greatest challenge to be tackled in computational modeling of pituitary gonadotropin signaling is the embedding of gonadotropin signaling within its natural multi-scale environment, from the single cell level, to the organic and whole HPG level. The development of modeling approaches of G protein-coupled receptor signaling, together with multicellular systems biology may lead to unexampled mechanistic understanding with critical expected fallouts in the therapeutic management of reproduction.
△ Less
Submitted 1 August, 2018;
originally announced August 2018.
-
Workflow description to dynamically model β-arrestin signaling networks
Authors:
Romain Yvinec,
Mohammed Akli Ayoub,
Francesco De Pascali,
Pascale Crépieux,
Eric Reiter,
Anne Poupon
Abstract:
Dynamic models of signaling networks allow the formulation of hypotheses on the topology and kinetic rate laws characterizing a given molecular network, in-depth exploration and confrontation with kinetic biological data. Despite its standardization, dynamic modeling of signaling networks still requires successive technical steps that need to be carefully performed. Here, we detail these steps by…
▽ More
Dynamic models of signaling networks allow the formulation of hypotheses on the topology and kinetic rate laws characterizing a given molecular network, in-depth exploration and confrontation with kinetic biological data. Despite its standardization, dynamic modeling of signaling networks still requires successive technical steps that need to be carefully performed. Here, we detail these steps by going through the mathematical and statistical framework. We explain how it can be applied to the understanding of β-arrestin-dependent signaling networks. We illustrate our methodology through the modeling of β-arrestin recruitment kinetics at the Follicle Stimulating Hormone (FSH) receptor supported by in-house Bioluminescence Resonance Energy Transfer (BRET) data.
△ Less
Submitted 31 July, 2018;
originally announced July 2018.
